SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.8008
-0.0067 (-0.83%)
At close: Jun 16, 2025, 4:00 PM
0.7850
-0.0158 (-1.97%)
After-hours: Jun 16, 2025, 4:00 PM EDT
SCYNEXIS Employees
SCYNEXIS had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
$93,929
Profits / Employee
-$967,500
Market Cap
31.25M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SCYX News
- 19 days ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 3 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 9 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 10 months ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 11 months ago - SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - GlobeNewsWire